tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Matthew Kaplan, 76 are a BUY (93.83%), 5 are a HOLD (6.17%).
Analyst Matthew Kaplan, carries an average stock price target met ratio of 48.56% that have a potential upside of 83.94% achieved within 237 days. Previously, Matthew Kaplan worked at LADENBURG.
Matthew Kaplan’s has documented 154 price targets and ratings displayed on 19 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on UTHR, United Therapeutics at 31-Oct-2024.
Analyst best performing recommendations are on AXSM (AXSOME THERAPEUTICS).
The best stock recommendation documented was for AXSM (AXSOME THERAPEUTICS) at 10/17/2018. The price target of $34 was fulfilled within 400 days with a profit of $30.08 (767.35%) receiving and performance score of 19.18.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 17-Apr-2023
$9
$5.92 (192.21%)
$19
2 months 10 days ago
(18-Aug-2026)
7/20 (35%)
$5.08 (129.59%)
247
Buy Since 26-Sep-2025
$15
$11.92 (387.01%)
$19
2 months 11 days ago
(17-Aug-2026)
14/24 (58.33%)
$10.94 (269.46%)
437
Buy Since 03-Mar-2016
$11
$7.92 (257.14%)
$14
2 months 18 days ago
(10-Aug-2026)
8/17 (47.06%)
$7 (175.00%)
307
Buy Since 04-Mar-2025
$14
$10.92 (354.55%)
$17
2 months 21 days ago
(07-Aug-2026)
0/7 (0%)
$10 (250.00%)
Buy Since 03-May-2024
$10
$6.92 (224.68%)
$10
2 months 21 days ago
(07-Aug-2026)
0/4 (0%)
$6 (150.00%)
